Your browser doesn't support javascript.
loading
Assessing immunogenicity barriers of the HIV-1 envelope trimer.
Maliqi, Liridona; Friedrich, Nikolas; Glögl, Matthias; Schmutz, Stefan; Schmidt, Daniel; Rusert, Peter; Schanz, Merle; Zaheri, Maryam; Pasin, Chloé; Niklaus, Cyrille; Foulkes, Caio; Reinberg, Thomas; Dreier, Birgit; Abela, Irene; Peterhoff, David; Hauser, Alexandra; Kouyos, Roger D; Günthard, Huldrych F; van Gils, Marit J; Sanders, Rogier W; Wagner, Ralf; Plückthun, Andreas; Trkola, Alexandra.
Afiliação
  • Maliqi L; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Friedrich N; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Glögl M; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Schmutz S; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Schmidt D; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Rusert P; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Schanz M; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Zaheri M; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Pasin C; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Niklaus C; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Foulkes C; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Reinberg T; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Dreier B; Department of Biochemistry, University of Zurich (UZH), Zurich, Switzerland.
  • Abela I; Department of Biochemistry, University of Zurich (UZH), Zurich, Switzerland.
  • Peterhoff D; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Hauser A; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Kouyos RD; Institute of Clinical Microbiology and Hygiene, University Hospital, Regensburg, Germany.
  • Günthard HF; Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.
  • van Gils MJ; Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.
  • Sanders RW; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Wagner R; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Plückthun A; Institute of Medical Virology, University of Zurich (UZH), Zurich, Switzerland.
  • Trkola A; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich (USZ), Zurich, Switzerland.
NPJ Vaccines ; 8(1): 148, 2023 Sep 30.
Article em En | MEDLINE | ID: mdl-37777519
ABSTRACT
Understanding the balance between epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of Env immunogens, we created a strategy based on synthetic, high diversity, Designed Ankyrin Repeat Protein (DARPin) libraries. We show that DARPin Antigenicity Analysis (DANA), a purely in vitro screening tool, has the capability to extrapolate relevant information of antigenic properties of Env immunogens. DANA screens of stabilized, soluble Env trimers revealed that stronger trimer stabilization led to the selection of highly mutated DARPins with length variations and framework mutations mirroring observations made for bnAbs. By mimicking heterotypic prime-boost immunization regimens, DANA may be used to select immunogen combinations that favor the selection of trimer-reactive binders. This positions DANA as a versatile strategy for distilling fundamental antigenic features of immunogens, complementary to preclinical immunogenicity testing.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: NPJ Vaccines Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: NPJ Vaccines Ano de publicação: 2023 Tipo de documento: Article